WO2010128807A3 - 신경손상 및 신경질환 예방 또는 치료용 약학조성물 - Google Patents

신경손상 및 신경질환 예방 또는 치료용 약학조성물 Download PDF

Info

Publication number
WO2010128807A3
WO2010128807A3 PCT/KR2010/002879 KR2010002879W WO2010128807A3 WO 2010128807 A3 WO2010128807 A3 WO 2010128807A3 KR 2010002879 W KR2010002879 W KR 2010002879W WO 2010128807 A3 WO2010128807 A3 WO 2010128807A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
preventing
neuronal damage
damage
neurological diseases
Prior art date
Application number
PCT/KR2010/002879
Other languages
English (en)
French (fr)
Other versions
WO2010128807A2 (ko
Inventor
정재훈
문형룡
Original Assignee
(주)문엔제이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)문엔제이 filed Critical (주)문엔제이
Priority to EP10772267A priority Critical patent/EP2428211A4/en
Priority to US13/319,304 priority patent/US20120053134A1/en
Priority to JP2012509731A priority patent/JP5826742B2/ja
Priority to CN201080020652.1A priority patent/CN102421440B/zh
Publication of WO2010128807A2 publication Critical patent/WO2010128807A2/ko
Publication of WO2010128807A3 publication Critical patent/WO2010128807A3/ko
Priority to US14/035,967 priority patent/US9168282B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

본 발명은 신경손상 및 신경질환 예방 또는 치료용 약학조성물에 관한 것으로, 보다 상세하게는 화학식 1의 화합물, 화학식 2의 화합물 및 이들의 가능한 염으로 이루어진 군에서 선택된 어느 하나의 화합물 또는 둘 이상의 화합물을 유효성분으로 함유하는 신경손상 및 신경질환 예방 또는 치료용 약학조성물에 관한 것이다. 이러한 약학조성물은 대상포진에 의해 손상된 신경조직을 수복하여 대상포진에 의한 급성통증을 감소시키고 대상포진후신경통으로의 이행을 차단할 수 있고, 대상포진후신경통에서도 신경조직의 수복을 통한 근본적인 치료를 가능하게 하며, 더나아가 좌골신경 압궤 손상 등을 포함하는 신경손상, 당뇨병성 신경병증 등을 포함하는 신경병증 및 신경병증성 통증, 뇌졸중 등을 포함하는 뇌질환을 비롯한 신경조직의 손상에 의해 초래되는 다양한 질환들에서도 매우 유용하게 사용될 수 있다.
PCT/KR2010/002879 2009-05-07 2010-05-06 신경손상 및 신경질환 예방 또는 치료용 약학조성물 WO2010128807A2 (ko)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP10772267A EP2428211A4 (en) 2009-05-07 2010-05-06 PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF NEURAL DAMAGE AND NEUROLOGICAL DISEASES
US13/319,304 US20120053134A1 (en) 2009-05-07 2010-05-06 Pharmaceutical composition for preventing or treating neuronal damage and neurological diseases
JP2012509731A JP5826742B2 (ja) 2009-05-07 2010-05-06 神経損傷及び神経疾患の予防または治療用薬学組成物
CN201080020652.1A CN102421440B (zh) 2009-05-07 2010-05-06 用于预防或治疗神经病理性疼痛的药学组合物
US14/035,967 US9168282B2 (en) 2009-05-07 2013-09-25 Method for treating neuronal damage and neurological diseases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20090039860 2009-05-07
KR10-2009-0039860 2009-05-07
KR1020100042276A KR101237927B1 (ko) 2009-05-07 2010-05-06 신경손상 및 신경질환 예방 또는 치료용 약학조성물
KR10-2010-0042276 2010-05-06

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/319,304 A-371-Of-International US20120053134A1 (en) 2009-05-07 2010-05-06 Pharmaceutical composition for preventing or treating neuronal damage and neurological diseases
US14/035,967 Continuation US9168282B2 (en) 2009-05-07 2013-09-25 Method for treating neuronal damage and neurological diseases

Publications (2)

Publication Number Publication Date
WO2010128807A2 WO2010128807A2 (ko) 2010-11-11
WO2010128807A3 true WO2010128807A3 (ko) 2011-03-31

Family

ID=43406759

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/002879 WO2010128807A2 (ko) 2009-05-07 2010-05-06 신경손상 및 신경질환 예방 또는 치료용 약학조성물

Country Status (6)

Country Link
US (2) US20120053134A1 (ko)
EP (1) EP2428211A4 (ko)
JP (1) JP5826742B2 (ko)
KR (1) KR101237927B1 (ko)
CN (1) CN102421440B (ko)
WO (1) WO2010128807A2 (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101398076B1 (ko) * 2011-06-24 2014-05-30 주식회사 아미팜 포스파티딜콜린을 유효성분으로 포함하는 항암제의 독성 감소용 조성물
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
DK2830645T3 (da) * 2012-03-30 2017-11-20 Acorda Therapeutics Inc Neuregulin til anvendelse i behandling af perifær nervelæsion
ES2691070T3 (es) 2012-05-11 2018-11-23 Kael-Gemvax Co.,Ltd Péptidos antiinflamatorios y composición que comprende los mismos
KR101508560B1 (ko) * 2012-05-24 2015-04-06 (주) 노바렉스 당세라마이드 유도체를 포함하는 기억력 개선, 인지능력 개선, 치매 예방 또는 치료 효과를 나타내는 약학적 조성물
JP6272853B2 (ja) 2012-07-11 2018-01-31 ジェムバックス アンド カエル カンパニー，リミティド 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
KR101552260B1 (ko) 2013-06-07 2015-09-10 주식회사 젬백스앤카엘 암의 면역학적 치료에 유용한 생물학적 마커
EP3011967B1 (en) 2013-06-21 2020-06-17 Gemvax & Kael Co., Ltd. Hormone secretion regulator, composition containing same, and method for controlling hormone secretion using same
KR102314231B1 (ko) 2013-12-17 2021-10-19 주식회사 젬백스앤카엘 전립선 암 치료용 조성물
JP6466971B2 (ja) 2014-04-30 2019-02-06 ジェムバックス アンド カエル カンパニー，リミティド 臓器、組織又は細胞移植用組成物、キット及び移植方法
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
EP3263122B1 (en) 2015-02-27 2020-05-06 Gemvax & Kael Co., Ltd. Peptide for preventing hearing loss, and composition comprising same
US11015179B2 (en) 2015-07-02 2021-05-25 Gemvax & Kael Co., Ltd. Peptide having anti-viral effect and composition containing same
JP6920324B2 (ja) 2015-11-03 2021-08-18 ジェムバックス アンド カエル カンパニー，リミティド 神経細胞の損失予防及び再生の効能を有するペプチド及びこれを含む組成物
WO2017176087A1 (ko) 2016-04-07 2017-10-12 주식회사 젬백스앤카엘 텔로머라제 활성 증가 및 텔로미어 연장 효능을 가지는 펩티드 및 이를 포함하는 조성물

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01135720A (ja) * 1987-11-20 1989-05-29 Eisai Co Ltd 神経線維再生剤
JPH06116149A (ja) * 1992-10-02 1994-04-26 Eisai Co Ltd 神経修復剤
JPH06157338A (ja) * 1992-11-27 1994-06-03 Sagami Chem Res Center 神経成長因子の産生促進剤
JP2004026803A (ja) * 2002-03-29 2004-01-29 Nof Corp 神経細胞死予防剤
JP2005272381A (ja) * 2004-03-25 2005-10-06 Q P Corp 末梢神経障害改善剤及びこれを含有する医薬品組成物、又は食品組成物
US20070243211A1 (en) * 2005-11-07 2007-10-18 Jaffe Russell M Compositions for regulating metabolic disorders and methods of use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4585656A (en) * 1984-08-20 1986-04-29 Rosenthal Harold R Treatment of herpes
JP2909508B2 (ja) * 1989-02-14 1999-06-23 マルハ株式会社 オキアミリン脂質の分取方法
US5463092A (en) * 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
AU1743495A (en) * 1994-02-04 1995-08-21 Cell Therapeutics, Inc. Composition for wound healing, neuron growth and vascularization
EP0850064A1 (en) * 1995-09-14 1998-07-01 Lxr Biotechnology Inc. Compositions with anti-apoptotic activity, containing a mixture of phospholipids
US6197830B1 (en) * 1995-09-22 2001-03-06 Bruce M. Frome Method for achieving relief from sympathetically mediated pain
US7582678B2 (en) * 1997-07-09 2009-09-01 D-Pharm Limited Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
US5874094A (en) * 1997-08-05 1999-02-23 Costello; Jeremiah Cream formulation for topical application
US6143278A (en) * 1998-02-23 2000-11-07 Elkhoury; George F. Topical application of opioid analgesic drugs such as morphine
EP1093348A4 (en) * 1998-06-29 2003-07-16 Pharmaceuticals Applic Asociat TRANSDERMAL ANALGESIC COMPOSITIONS AND METHODS OF ADMINISTRATION
US6080744A (en) * 1999-02-10 2000-06-27 Ayon-Covarrubias; Blas Topical antifungal treatment
AU7057700A (en) * 1999-08-18 2001-03-13 Atairgin Technologies, Inc. Compounds which modulate the activity of an lpa receptor
EP1389119A4 (en) 2001-04-25 2006-04-12 Biosynergen Inc PHARMACEUTICAL COMPOSITION BASED ON LYSOPHOSPHATIDE ACID
US7202040B2 (en) 2001-12-14 2007-04-10 Takeda Pharmaceutical Company Limited Method for screening compounds which change the binding properties of a protein with a ligand
JP2007119361A (ja) * 2005-10-25 2007-05-17 Nagase Chemtex Corp ホスホリパーゼａ２阻害剤
US20080051372A1 (en) * 2006-08-24 2008-02-28 The Scripps Research Institute Methods utilizing cell-signaling lysophospholipids
US9511016B2 (en) * 2007-06-12 2016-12-06 Epicentrx, Inc. Topical composition for treating pain

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01135720A (ja) * 1987-11-20 1989-05-29 Eisai Co Ltd 神経線維再生剤
JPH06116149A (ja) * 1992-10-02 1994-04-26 Eisai Co Ltd 神経修復剤
JPH06157338A (ja) * 1992-11-27 1994-06-03 Sagami Chem Res Center 神経成長因子の産生促進剤
JP2004026803A (ja) * 2002-03-29 2004-01-29 Nof Corp 神経細胞死予防剤
JP2005272381A (ja) * 2004-03-25 2005-10-06 Q P Corp 末梢神経障害改善剤及びこれを含有する医薬品組成物、又は食品組成物
US20070243211A1 (en) * 2005-11-07 2007-10-18 Jaffe Russell M Compositions for regulating metabolic disorders and methods of use thereof

Also Published As

Publication number Publication date
WO2010128807A2 (ko) 2010-11-11
US20140030366A1 (en) 2014-01-30
US20120053134A1 (en) 2012-03-01
EP2428211A2 (en) 2012-03-14
JP5826742B2 (ja) 2015-12-02
CN102421440A (zh) 2012-04-18
EP2428211A4 (en) 2013-04-03
KR20100121424A (ko) 2010-11-17
JP2012526104A (ja) 2012-10-25
KR101237927B1 (ko) 2013-03-04
US9168282B2 (en) 2015-10-27
CN102421440B (zh) 2017-06-09

Similar Documents

Publication Publication Date Title
WO2010128807A3 (ko) 신경손상 및 신경질환 예방 또는 치료용 약학조성물
MX2015008396A (es) Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen.
TW200744586A (en) Therapeutic compounds
WO2007129195A3 (en) 4-pyrimidine-5-amino-pyrazole compounds
NZ591810A (en) Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid
WO2006073448A3 (en) Methods and compositions for treating diseases and conditions associated with mitochondrial function
WO2010088000A3 (en) Antifibrotic compounds and uses thereof
BR112012009215A2 (pt) "terapia combinada contra o cancer com compostos inibidores de hsp90"
TW200639159A (en) Treatment of pain
WO2006116733A3 (en) Protein kinase inhibitors
WO2009066041A3 (fr) Derives de 1,2,4,5-tetrahydro-3h-benzazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2011011882A8 (en) Hydroxy fatty acid compounds and uses thereof for disease treatment and diagnosis
WO2010107807A3 (en) Compounds for treating inflammation and pain
WO2018070854A3 (ko) 모노아세틸디아실글리세롤 화합물을 함유하는 간염의 예방 또는 치료용 조성물
WO2009094560A3 (en) Thienopyranones as kinase inhibitors
EP1905442A4 (en) USE OF ANTINEUROPATHIC PAIN EFFECT OF D-ALLOSIS AND D-PSICOSIS
PH12014502813A1 (en) Aqueous alcoholic microbicidal compositions comprising zinc ions
WO2010005528A3 (en) Pyrrolopyridine carboxylic acid derivatives
WO2010021750A3 (en) Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer
MA32243B1 (fr) Composition bactéricide destinée à l'agriculture et à l'horticulture et procédé de prévention contre les maladies des plantes
WO2009096667A3 (ko) 신규한 퀴나졸린-2,4-디온 유도체 및 이를 함유하는 뇌신경질환 예방 및 치료용 의약 조성물
WO2009093864A3 (ko) 뇌질환의 예방 또는 치료용 조성물
HK1129071A1 (en) Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels
WO2009022842A3 (en) Pharmaceutical composition for preventing and treating cell proliferative disease comprising mixture of feather of birds and scale of fish as an active ingredient
TW201129376A (en) A screening method of a medicament effective for treating dry eye and/or corneal/conjunctival disorders and a pharmaceutical composition obtained from the method

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080020652.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10772267

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2012509731

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13319304

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2010772267

Country of ref document: EP